What is the estimated Carbapenem-Resistant Enterobacteriaceae (CRE) fecal carriage rate in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The estimated Carbapenem-Resistant Enterobacteriaceae (CRE) fecal carriage rate in India is approximately 18.1% in hospitalized patients, as reported in a study published in the Indian Journal of Medical Microbiology in 2017 1. This rate is concerning, given the potential for CRE carriers to transmit the bacteria to others and develop difficult-to-treat infections themselves. The carriage rate may vary based on factors such as geographic location, healthcare exposure, and antibiotic use patterns. Some key points to consider include:

  • The study found that 42 out of 232 patients (18.1%) were colonized with CRE, with 27 isolates carrying the blaNDM-1 gene and 20 isolates carrying the blaVIM gene 1.
  • The presence of any indwelling device and nasogastric tube were identified as independent risk factors for acquiring gut colonization with CRE 1.
  • The widespread use of broad-spectrum antibiotics, variable infection control practices, and high population density may contribute to the elevated carriage rates in India.
  • Regular surveillance, antimicrobial stewardship, and improved infection control measures are essential to address this public health challenge. It is worth noting that other studies have reported varying rates of CRE carriage, but the study by 1 provides the most relevant and recent data on this topic in the Indian context.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.